Do you want to enhance your plasmid DNA extraction skills? Join us for an illuminating webinar with plasmid DNA expert Dr. Thorsten Singer, where you'll learn how to:

• Handle bacterial cultures
• Purify plasmid DNA using different technologies
• Avoid RNA and endotoxin contamination 

This is an excellent opportunity to boost your knowledge and skills. 
Can't make the live session? Register to receive a link to the recorded webinar and gain access anytime, anywhere. 

Do you want to enhance your plasmid DNA extraction skills? Join us for an illuminating webinar with plasmid DNA expert Dr. Thorsten Singer, where you'll learn how to:

• Handle bacterial cultures
• Purify plasmid DNA using different technologies
• Avoid RNA and endotoxin contamination 

This is an excellent opportunity to boost your knowledge and skills. 
Can't make the live session? Register to receive a link to the recorded webinar and gain access anytime, anywhere. 

Join this expert webinar with Dr. George Quellhorst as he shows how to easily analyze miRNA-seq data using the RNA-seq Analysis Portal – an intuitive, web-based data analysis tool.

Get to focus on comparing your samples the way you want and make the publication-quality heat maps and volcano plots you need. Use our RNA-seq Analysis Portal (access included with QIAseq miRNA Library Kits) to gain biological insights and plan follow-up experiments from your results. 

Don’t miss this webinar. Learn how to analyze your QIAseq miRNA Library Kit data using the RNA-seq Analysis Portal with ease and confidence.

The potential of artificial intelligence (AI) in clinical genomics is causing some diagnostic labs to consider how the technology can improve time-consuming components of their workflow—especially variant curation. The primary bottleneck to achieving accurate and comprehensive variant curation is the need to manually locate, assess, annotate and document evidence from scientific and clinical literature. While AI is a logical solution to these challenges, can diagnostic labs trust it?

In this webinar, we examine a new study by Stanford University that analyzes the accuracy, consistency, and comprehensiveness of automated and manual germline variant curation. The study compares the quality of data from Stanford’s Automatic VAriant evidence DAtabase (AVADA) to the Human Gene Mutation Database (HGMD), an expert-curated resource for human inherited disease mutations.

By attending this webinar, you will:

• Analyze a series of use-cases comparing the performance of AI-driven variant curation to manual approaches
• Receive a virtual demonstration of how HGMD presents mutation data, including how the database provides genomic coordinates, Human Genome Variation Society (HGVS) nomenclatures for variants, citations from key publications, and where a variant is described in a paper or supplemental text
• Learn how HGMD simplifies literature review and supports CNV interpretation
• Receive a complimentary 5-day trial of HGMD Professional

The potential of artificial intelligence (AI) in clinical genomics is causing some diagnostic labs to consider how the technology can improve time-consuming components of their workflow—especially variant curation. The primary bottleneck to achieving accurate and comprehensive variant curation is the need to manually locate, assess, annotate and document evidence from scientific and clinical literature. While AI is a logical solution to these challenges, can diagnostic labs trust it?

In this webinar, we examine a new study by Stanford University that analyzes the accuracy, consistency, and comprehensiveness of automated and manual germline variant curation. The study compares the quality of data from Stanford’s Automatic VAriant evidence DAtabase (AVADA) to the Human Gene Mutation Database (HGMD), an expert-curated resource for human inherited disease mutations.

By attending this webinar, you will:

• Analyze a series of use-cases comparing the performance of AI-driven variant curation to manual approaches
• Receive a virtual demonstration of how HGMD presents mutation data, including how the database provides genomic coordinates, Human Genome Variation Society (HGVS) nomenclatures for variants, citations from key publications, and where a variant is described in a paper or supplemental text
• Learn how HGMD simplifies literature review and supports CNV interpretation
• Receive a complimentary 5-day trial of HGMD Professional

The potential of artificial intelligence (AI) in clinical genomics is causing some diagnostic labs to consider how the technology can improve time-consuming components of their workflow—especially variant curation. The primary bottleneck to achieving accurate and comprehensive variant curation is the need to manually locate, assess, annotate and document evidence from scientific and clinical literature. While AI is a logical solution to these challenges, can diagnostic labs trust it?

In this webinar, we examine a new study by Stanford University that analyzes the accuracy, consistency, and comprehensiveness of automated and manual germline variant curation. The study compares the quality of data from Stanford’s Automatic VAriant evidence DAtabase (AVADA) to the Human Gene Mutation Database (HGMD), an expert-curated resource for human inherited disease mutations.

By attending this webinar, you will:

• Analyze a series of use-cases comparing the performance of AI-driven variant curation to manual approaches
• Receive a virtual demonstration of how HGMD presents mutation data, including how the database provides genomic coordinates, Human Genome Variation Society (HGVS) nomenclatures for variants, citations from key publications, and where a variant is described in a paper or supplemental text
• Learn how HGMD simplifies literature review and supports CNV interpretation
• Receive a complimentary 5-day trial of HGMD Professional

The potential of artificial intelligence (AI) in clinical genomics is causing some diagnostic labs to consider how the technology can improve time-consuming components of their workflow—especially variant curation. The primary bottleneck to achieving accurate and comprehensive variant curation is the need to manually locate, assess, annotate and document evidence from scientific and clinical literature. While AI is a logical solution to these challenges, can diagnostic labs trust it?

In this webinar, we examine a new study by Stanford University that analyzes the accuracy, consistency, and comprehensiveness of automated and manual germline variant curation. The study compares the quality of data from Stanford’s Automatic VAriant evidence DAtabase (AVADA) to the Human Gene Mutation Database (HGMD), an expert-curated resource for human inherited disease mutations.

By attending this webinar, you will:

• Analyze a series of use-cases comparing the performance of AI-driven variant curation to manual approaches
• Receive a virtual demonstration of how HGMD presents mutation data, including how the database provides genomic coordinates, Human Genome Variation Society (HGVS) nomenclatures for variants, citations from key publications, and where a variant is described in a paper or supplemental text
• Learn how HGMD simplifies literature review and supports CNV interpretation
• Receive a complimentary 5-day trial of HGMD Professional

Discovery of new genes implicated in hereditary diseases or cancer progression is challenging and advancing rapidly with an increase in the amount of cohort data to analyze. It is estimated that every day one new gene is discovered to be associated with a disease. QCI Interpret Translational can get your research to the next level by providing you all the necessary analysis tools with the world’s most comprehensive and up-to-date curated scientific evidence. Get valuable and reliable insights for your research project and speed up your discoveries by using a streamlined NGS analysis workflow in a user-friendly interface without needing bioinformatics expertise. 

In this webinar, attendees will have the opportunity to:

• Explore capabilities which can enable them to accelerate discoveries from hereditary or tumor cohort analyses
• Discover interactive tools with current and comprehensive associations between gene variants and diseases
• Learn how these resources are supported by unique curated content among other integrated scientific evidence

Discovery of new genes implicated in hereditary diseases or cancer progression is challenging and advancing rapidly with an increase in the amount of cohort data to analyze. It is estimated that every day one new gene is discovered to be associated with a disease. QCI Interpret Translational can get your research to the next level by providing you all the necessary analysis tools with the world’s most comprehensive and up-to-date curated scientific evidence. Get valuable and reliable insights for your research project and speed up your discoveries by using a streamlined NGS analysis workflow in a user-friendly interface without needing bioinformatics expertise. 

In this webinar, attendees will have the opportunity to:

• Explore capabilities which can enable them to accelerate discoveries from hereditary or tumor cohort analyses
• Discover interactive tools with current and comprehensive associations between gene variants and diseases
• Learn how these resources are supported by unique curated content among other integrated scientific evidence

Discovery of new genes implicated in hereditary diseases or cancer progression is challenging and advancing rapidly with an increase in the amount of cohort data to analyze. It is estimated that every day one new gene is discovered to be associated with a disease. QCI Interpret Translational can get your research to the next level by providing you all the necessary analysis tools with the world’s most comprehensive and up-to-date curated scientific evidence. Get valuable and reliable insights for your research project and speed up your discoveries by using a streamlined NGS analysis workflow in a user-friendly interface without needing bioinformatics expertise. 

In this webinar, attendees will have the opportunity to:

• Explore capabilities which can enable them to accelerate discoveries from hereditary or tumor cohort analyses
• Discover interactive tools with current and comprehensive associations between gene variants and diseases
• Learn how these resources are supported by unique curated content among other integrated scientific evidence

Discovery of new genes implicated in hereditary diseases or cancer progression is challenging and advancing rapidly with an increase in the amount of cohort data to analyze. It is estimated that every day one new gene is discovered to be associated with a disease. QCI Interpret Translational can get your research to the next level by providing you all the necessary analysis tools with the world’s most comprehensive and up-to-date curated scientific evidence. Get valuable and reliable insights for your research project and speed up your discoveries by using a streamlined NGS analysis workflow in a user-friendly interface without needing bioinformatics expertise. 

In this webinar, attendees will have the opportunity to:

• Explore capabilities which can enable them to accelerate discoveries from hereditary or tumor cohort analyses
• Discover interactive tools with current and comprehensive associations between gene variants and diseases
• Learn how these resources are supported by unique curated content among other integrated scientific evidence

Although there have been remarkable improvements in genomics, interpreting NGS data for hereditary diseases remains difficult. The field is constantly changing, and numerous new articles on human genetic variants are added to PubMed each week. For genetic testing labs, overlooking even a single article among millions can make a significant difference between an inconclusive result and a diagnosis.

In this webinar, we will demonstrate how QCI Interpret can improve your diagnostic yield for hereditary disorders. QCI Interpret is a clinical decision support platform that leverages augmented molecular intelligence to streamline the interpretation workflow. It uses the most extensive, globally trusted and manually curated molecular knowledge and bibliography evidence to provide you with the best possible opportunity to solve every case. By demonstrating the different features and series of use-cases, we will show you how QCI Interpret guarantees a comprehensive and thorough investigation of every case for all types of genetic variation, including copy number variants (CNVs). This will allow you to provide precise answers to patients and their families, while also reducing test turnaround time from hours to minutes.

Learning objectives:

• Learn about QCI Interpret’s analysis and interpretation workflow for hereditary diseases using targeted and extended gene panels, including WES/WGS
• Learn about QCI Interpret and QIAGEN’s expert curation process based on the latest ACMG carrier screening guidelines 
• View demonstrations of unique features in QCI Interpret, including how to input symptoms relevant to a case and receive relationships to candidate diseases and mutated genes using the Phenotype Network Analysis feature and triage mode of variant assessment.
• Learn how QCI Interpret supports CNV interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports"

Although there have been remarkable improvements in genomics, interpreting NGS data for hereditary diseases remains difficult. The field is constantly changing, and numerous new articles on human genetic variants are added to PubMed each week. For genetic testing labs, overlooking even a single article among millions can make a significant difference between an inconclusive result and a diagnosis.

In this webinar, we will demonstrate how QCI Interpret can improve your diagnostic yield for hereditary disorders. QCI Interpret is a clinical decision support platform that leverages augmented molecular intelligence to streamline the interpretation workflow. It uses the most extensive, globally trusted and manually curated molecular knowledge and bibliography evidence to provide you with the best possible opportunity to solve every case. By demonstrating the different features and series of use-cases, we will show you how QCI Interpret guarantees a comprehensive and thorough investigation of every case for all types of genetic variation, including copy number variants (CNVs). This will allow you to provide precise answers to patients and their families, while also reducing test turnaround time from hours to minutes.

Learning objectives:

• Learn about QCI Interpret’s analysis and interpretation workflow for hereditary diseases using targeted and extended gene panels, including WES/WGS
• Learn about QCI Interpret and QIAGEN’s expert curation process based on the latest ACMG carrier screening guidelines 
• View demonstrations of unique features in QCI Interpret, including how to input symptoms relevant to a case and receive relationships to candidate diseases and mutated genes using the Phenotype Network Analysis feature and triage mode of variant assessment.
• Learn how QCI Interpret supports CNV interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports"

Although there have been remarkable improvements in genomics, interpreting NGS data for hereditary diseases remains difficult. The field is constantly changing, and numerous new articles on human genetic variants are added to PubMed each week. For genetic testing labs, overlooking even a single article among millions can make a significant difference between an inconclusive result and a diagnosis.

In this webinar, we will demonstrate how QCI Interpret can improve your diagnostic yield for hereditary disorders. QCI Interpret is a clinical decision support platform that leverages augmented molecular intelligence to streamline the interpretation workflow. It uses the most extensive, globally trusted and manually curated molecular knowledge and bibliography evidence to provide you with the best possible opportunity to solve every case. By demonstrating the different features and series of use-cases, we will show you how QCI Interpret guarantees a comprehensive and thorough investigation of every case for all types of genetic variation, including copy number variants (CNVs). This will allow you to provide precise answers to patients and their families, while also reducing test turnaround time from hours to minutes.

Learning objectives:

• Learn about QCI Interpret’s analysis and interpretation workflow for hereditary diseases using targeted and extended gene panels, including WES/WGS
• Learn about QCI Interpret and QIAGEN’s expert curation process based on the latest ACMG carrier screening guidelines 
• View demonstrations of unique features in QCI Interpret, including how to input symptoms relevant to a case and receive relationships to candidate diseases and mutated genes using the Phenotype Network Analysis feature and triage mode of variant assessment.
• Learn how QCI Interpret supports CNV interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports"

Although there have been remarkable improvements in genomics, interpreting NGS data for hereditary diseases remains difficult. The field is constantly changing, and numerous new articles on human genetic variants are added to PubMed each week. For genetic testing labs, overlooking even a single article among millions can make a significant difference between an inconclusive result and a diagnosis.

In this webinar, we will demonstrate how QCI Interpret can improve your diagnostic yield for hereditary disorders. QCI Interpret is a clinical decision support platform that leverages augmented molecular intelligence to streamline the interpretation workflow. It uses the most extensive, globally trusted and manually curated molecular knowledge and bibliography evidence to provide you with the best possible opportunity to solve every case. By demonstrating the different features and series of use-cases, we will show you how QCI Interpret guarantees a comprehensive and thorough investigation of every case for all types of genetic variation, including copy number variants (CNVs). This will allow you to provide precise answers to patients and their families, while also reducing test turnaround time from hours to minutes.

Learning objectives:

• Learn about QCI Interpret’s analysis and interpretation workflow for hereditary diseases using targeted and extended gene panels, including WES/WGS
• Learn about QCI Interpret and QIAGEN’s expert curation process based on the latest ACMG carrier screening guidelines 
• View demonstrations of unique features in QCI Interpret, including how to input symptoms relevant to a case and receive relationships to candidate diseases and mutated genes using the Phenotype Network Analysis feature and triage mode of variant assessment.
• Learn how QCI Interpret supports CNV interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports"

Zoonotic viruses, such as influenza A, can overcome species barriers to pose a serious threat to human health. Understanding the entry mechanism of these viruses is essential to grasping their full tropism and zoonotic potential. But efforts to identify virus-cell interactions are frequently impeded as these interactions take place at very low levels. 

In this webinar, join Prof. Dr. Martin Schwemmle from University of Freiburg, as he discusses his Nature publication on identifying the entry mediator for bat influenza A viruses in multiple species, using PICO technology. 

The webinar will cover:

• PICO as a protein-protein interaction approach based on digital PCR
• How PICO and other methods were used to identify and confirm MHC class II proteins as mediators of cross-species entry of bat influenza viruses
• Future directions for PICO technology and viral research

Zoonotic viruses, such as influenza A, can overcome species barriers to pose a serious threat to human health. Understanding the entry mechanism of these viruses is essential to grasping their full tropism and zoonotic potential. But efforts to identify virus-cell interactions are frequently impeded as these interactions take place at very low levels. 

In this webinar, join Prof. Dr. Martin Schwemmle from University of Freiburg, as he discusses his Nature publication on identifying the entry mediator for bat influenza A viruses in multiple species, using PICO technology. 

The webinar will cover:

• PICO as a protein-protein interaction approach based on digital PCR
• How PICO and other methods were used to identify and confirm MHC class II proteins as mediators of cross-species entry of bat influenza viruses
• Future directions for PICO technology and viral research